Age, Biography and Wiki
Nathaniel David was born on 27 December, 1967 in San Francisco, California, U.S., is an American scientist and entrepreneur. Discover Nathaniel David's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 56 years old?
| Popular As |
N/A |
| Occupation |
N/A |
| Age |
56 years old |
| Zodiac Sign |
Capricorn |
| Born |
27 December 1967 |
| Birthday |
27 December |
| Birthplace |
San Francisco, California, U.S. |
| Nationality |
United States
|
We recommend you to check the complete list of Famous People born on 27 December.
He is a member of famous Entrepreneur with the age 56 years old group.
Nathaniel David Height, Weight & Measurements
At 56 years old, Nathaniel David height not available right now. We will update Nathaniel David's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
Nathaniel David Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Nathaniel David worth at the age of 56 years old? Nathaniel David’s income source is mostly from being a successful Entrepreneur. He is from United States. We have estimated Nathaniel David's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
Entrepreneur |
Nathaniel David Social Network
Timeline
Nathaniel David is an American scientist and entrepreneur who co-founded a series of technology companies in the biotechnology and sustainable energy sectors, including Syrrx (acquired by Takeda Pharmaceutical Company), Achaogen (NASDAQ: AKAO), Kythera Biopharmaceuticals (NASDAQ: KYTH, acquired by Allergan), Sapphire Energy and Unity Biotechnology.
These companies have collectively raised more than $1.5 billion in financing.
David earned an A.B. in Biology from Harvard University and a Ph.D. in Molecular and Cellular Biology from University of California, Berkeley.
He co-founded his first company, Syrrx, during the final year of his doctoral work at UC Berkeley.
Syrrx was the first company in the world to build a high-throughput structural biology ‘factory,’ using automation, nano-scale experiments, and crystallography to make the determination of atomic structures of proteins easier, faster, and cheaper.
In 2002, while at Syrrx, he was named to the MIT Technology Review TR35 as one of the top 35 innovators in the world under the age of 35.
In 2005, Syrrx was acquired by Takeda, and the FDA-approved drug Nesina arose from Syrrx discovery efforts.
David left Syrrx to co-found Achaogen (NASDAQ: AKAO), an antibiotic company, and Kythera Biopharmaceticals (NASDAQ: KYTH).
He served as Chief Science Officer of Kythera while the company created a now-FDA-approved injectable drug Kybella that triggers the selective destruction of fat cells.
In 2007, while still serving as Chief Science Officer at Kythera, David co-founded Sapphire Energy, a company with a mission to develop renewable, algae-derived transportation fuels that are 100% compliant with the existing energy infrastructure.
In 2010, the company began construction of the world's first commercial algal bio-refinery, a project that was awarded more than $100 million in federal funding.
In 2011, David co-founded Unity Biotechnology (NASDAQ: UBX), a company dedicated to lengthening human healthspan by selectively clearing senescent cells from the body.
UNITY is creating medicines that target multiple diseases of aging.
David is currently the President of Unity Biotechnology.
Kythera went public in October 2012 on the NASDAQ exchange under the ticker symbol KYTH, and was acquired by Allergan in 2015 for $2.1 billion.
Achaogen's antibiotic plazomicin is effective against multidrug-resistant infections of Enterobacteriaceae.
In 2016, plazomicin demonstrated noninferiority for urinary tract infections (UTIs) in a pivotal phase III trial against colistin, and against meropenem for complicated UTIs and acute pyelonephritis.
The U.S. Food and Drug Administration (FDA) approved plazomicin for adults with complicated UTIs and limited or no alternative treatment options in 2018; it is now sold under the brand name Zemdri.
In April 2019, Achaogen declared bankrupt.
